Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Brendan Clark, Brian J Wells, Amit K Saha, Jessica Franchino-Elder, Asif Shaikh, Bonnie M K Donato & Jill A Ohar. (2022) Low Peak Inspiratory Flow Rates are Common Among COPD Inpatients and are Associated with Increased Healthcare Resource Utilization: A Retrospective Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 1483-1494.
Read now
Read now
Jill A Ohar, Gary T Ferguson, Donald A Mahler, M Bradley Drummond, Rajiv Dhand, Roy A Pleasants, Antonio Anzueto, David M G Halpin, David B Price, Gail S Drescher, Haley M Hoy, John Haughney, Michael W Hess & Omar S Usmani. (2022) Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 79-92.
Read now
Read now
Luis Perez de Llano, Elsa Naval, Natalia Mejía & Javier Domínguez-Ortega. (2022) Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma. Expert Review of Respiratory Medicine 16:1, pages 1-15.
Read now
Read now
A. H. de Boer, P. Hagedoorn, M. Hoppentocht, F. Buttini, F. Grasmeijer & H. W. Frijlink. (2017) Dry powder inhalation: past, present and future. Expert Opinion on Drug Delivery 14:4, pages 499-512.
Read now
Read now
Tan Suwandecha, Wibul Wongpoowarak & Teerapol Srichana. (2016) Computer-aided design of dry powder inhalers using computational fluid dynamics to assess performance. Pharmaceutical Development and Technology 21:1, pages 54-60.
Read now
Read now
Georges Juvelekian, Waleed El-Sorougi, Chaicharn Pothirat, Faisal Yunus, Teresita De Guia, Han-Pin Kuo, Shalma Basu Patnaik & Virginia Pilipovic. (2015) A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 2109-2120.
Read now
Read now
Anoop Prakash, K Suresh Babu & Jaymin B Morjaria. (2015) Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 111-123.
Read now
Read now
Andrea Rossi, Erika Zanardi, Venerino Poletti & Mario Cazzola. (2015) Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1383-1392.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani & Mario Cazzola. (2015) QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 16:7, pages 1079-1090.
Read now
Read now
J Christian Virchow, Thomas Weuthen, Quentin J Harmer & Spencer Jones. (2014) Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opinion on Drug Delivery 11:12, pages 1849-1857.
Read now
Read now
Eric D Bateman, Donald A Mahler, Claus F Vogelmeier, Jadwiga A Wedzicha, Francesco Patalano & Donald Banerji. (2014) Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Review of Respiratory Medicine 8:3, pages 357-379.
Read now
Read now
Anthony D’Urzo. (2013) Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD. Therapeutics and Clinical Risk Management 9, pages 341-353.
Read now
Read now
Mathieu Molimard & Peter D’Andrea. (2013) Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile. Expert Review of Clinical Pharmacology 6:5, pages 503-517.
Read now
Read now
Paul Colthorpe, Thomas Voshaar, Thomas Kieckbusch, Erika Cuoghi & Juergen Jauernig. (2013) Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. Journal of Drug Assessment 2:1, pages 11-16.
Read now
Read now
Roland Buhl & Donald Banerji. (2012) Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 729-741.
Read now
Read now
Kenneth R Chapman, Charles M Fogarty, Clare Peckitt, Cheryl Lassen, Dalal Jadayel, Juergen Dederichs, Mukul Dalvi & Benjamin Kramer. (2011) Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. International Journal of Chronic Obstructive Pulmonary Disease 6, pages 353-363.
Read now
Read now
Christopher KM Hui & Kian F Chung. (2011) Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD. Expert Review of Respiratory Medicine 5:1, pages 9-16.
Read now
Read now
Articles from other publishers (59)
José Luis Lopez-Campos, Rocio Reinoso-Arija, Marta Ferrer Galván, Auxiliadora Romero Falcón, Francisco J. Alvarez-Gutiérrez, Francisco Ortega-Ruiz & Esther Quintana-Gallego. (2023) Evaluation of Different Doses in Inhaled Therapy: A Comprehensive Analysis. Pharmaceutics 15:9, pages 2206.
Crossref
Crossref
Yuqing Ye, Ying Ma, Ziyi Fan & Jesse Zhu. (2022) The effects of grid design on the performance of 3D-printed dry powder inhalers. International Journal of Pharmaceutics 627, pages 122230.
Crossref
Crossref
Jeffry Weers. (2022) Suboptimal Inspiratory Flow Rates With Passive Dry Powder Inhalers: Big Issue or Overstated Problem?. Frontiers in Drug Delivery 2.
Crossref
Crossref
Hadeer S. Harb, Nabila Ibrahim Laz, Hoda Rabea, Yasmin M. Madney, Marian S. Boshra & Mohamed E. A. Abdelrahim. (2021) Aerosol drug‐delivery and short‐term clinical outcomes of suboptimal peak inspiratory flow rate in chronic obstructive pulmonary disease. International Journal of Clinical Practice 75:12.
Crossref
Crossref
Francesca Buttini, Eride Quarta, Chiara Allegrini & Federico Lavorini. (2021) Understanding the Importance of Capsules in Dry Powder Inhalers. Pharmaceutics 13:11, pages 1936.
Crossref
Crossref
Mathieu Molimard, Ioannis Kottakis, Juergen Jauernig, Sonja Lederhilger & Ivan Nikolaev. (2021) Performance Characteristics of Breezhaler® and Aerolizer® in the Real-World Setting. Clinical Drug Investigation 41:5, pages 415-424.
Crossref
Crossref
A. V. BadarinathS A SreenivasM. Suresh Babu. (2021) REVIEW ON DRY POWDER INHALERS: CURRENT ADVANCES AND LIMITATIONS. PARIPEX INDIAN JOURNAL OF RESEARCH, pages 63-67.
Crossref
Crossref
Mohamad Abadelah, Gaballa Abdalla, Henry Chrystyn & Hassan Larhrib. (2021) Gaining an insight into the importance of each inhalation manoeuvre parameter using altered patients’ inhalation profiles. Journal of Drug Delivery Science and Technology 61, pages 102181.
Crossref
Crossref
Mellissa Gomez, Joseph McCollum, Hui Wang, Mani Ordoubadi, Chester Jar, Nicholas B. Carrigy, David Barona, Isobel Tetreau, Michelle Archer, Alana Gerhardt, Chris Press, Christopher B. Fox, Ryan M. Kramer & Reinhard Vehring. (2021) Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate. International Journal of Pharmaceutics 593, pages 120121.
Crossref
Crossref
Alpár Horváth, Árpád Farkas, Annamária Szipőcs, Gábor Tomisa, Zsuzsanna Szalai & Gabriella Gálffy. (2020) Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients. European Journal of Pharmaceutical Sciences 154, pages 105508.
Crossref
Crossref
Fatima Aloum, Yuosef Al Ayoub, M.A. Mohammad, Muthana Obeed, K. Paluch & K.H. Assi. (2020) Ex vivo and in vitro evaluation of the influence of the inhaler device and formulation on lung deposition of budesonide. Powder Technology 372, pages 685-693.
Crossref
Crossref
Roland Buhl, Ana-Maria Tanase, Motoi Hosoe, Weihua Cao, Ivan Demin, Christian Bartels, Jürgen Jauernig, Dominik Ziegler, Francesco Patalano, Bettina Hederer, Frank Kanniess & Hanns-Christian Tillmann. (2020) A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma. Pulmonary Pharmacology & Therapeutics 62, pages 101919.
Crossref
Crossref
Shih-Yu Chen, Chun-Kai Huang, Hui-Chuan Peng, Chong-Jen Yu & Jung-Yien Chien. (2020) Inappropriate Peak Inspiratory Flow Rate with Dry Powder Inhaler in Chronic Obstructive Pulmonary Disease. Scientific Reports 10:1.
Crossref
Crossref
Yongquan Li, Adam Bohr, Henrik Jensen, Jukka Rantanen, Claus Cornett, Moritz Beck-Broichsitter & Johan Peter Bøtker. (2020) Medication Tracking: Design and Fabrication of a Dry Powder Inhaler with Integrated Acoustic Element by 3D Printing. Pharmaceutical Research 37:3.
Crossref
Crossref
Donald A. Mahler. (2020) The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respiratory Medicine 161, pages 105857.
Crossref
Crossref
Myrna B. Dolovich, Andreas Kuttler, Thomas J. Dimke & Omar S. Usmani. (2019) Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler. International Journal of Pharmaceutics: X 1, pages 100018.
Crossref
Crossref
Mohamad Abadelah, Henry Chrystyn & Hassan Larhrib. (2019) Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler. European Journal of Pharmaceutical Sciences 134, pages 138-144.
Crossref
Crossref
Anthony D’Urzo, Kenneth R. Chapman, James F. Donohue, Peter Kardos, M. Reza Maleki-Yazdi & David Price. (2019) Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. Pulmonary Therapy 5:1, pages 23-41.
Crossref
Crossref
Pablo Altman, Luis Wehbe, Juergen Dederichs, Tadhg Guerin, Brian Ament, Miguel Cardenas Moronta, Andrea Valeria Pino & Pankaj Goyal. (2018) Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulmonary Medicine 18:1.
Crossref
Crossref
Conor A. RuzyckiAndrew R. MartinReinhard VehringWarren H. Finlay. (2018)
An
In Vitro
Examination of the Effects of Altitude on Dry Powder Inhaler Performance
. Journal of Aerosol Medicine and Pulmonary Drug Delivery 31:4, pages 221-236.
Crossref
Crossref
Daiki Hira, Hiroyoshi Koide, Shigemi Nakamura, Toyoko Okada, Kazunori Ishizeki, Masafumi Yamaguchi, Setsuko Koshiyama, Tetsuya Oguma, Kayoko Ito, Saori Funayama, Yuko Komase, Shin-ya Morita, Kohshi Nishiguchi, Yasutaka Nakano & Tomohiro Terada. (2018) Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices. PLOS ONE 13:2, pages e0193082.
Crossref
Crossref
Francesca Buttini, Stavroula Rozou, Alessandra Rossi, Varvara Zoumpliou & Dimitrios M. Rekkas. (2018) The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers. European Journal of Pharmaceutical Sciences 113, pages 64-76.
Crossref
Crossref
Mohamad Abadelah, Henry Chrystyn, Golshan Bagherisadeghi, Gaballa Abdalla & Hassan Larhrib. (2017) Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg. AAPS PharmSciTech 19:1, pages 251-261.
Crossref
Crossref
Federico Lavorini, Massimo Pistolesi & Omar S. Usmani. (2017) Recent advances in capsule-based dry powder inhaler technology. Multidisciplinary Respiratory Medicine 12:1.
Crossref
Crossref
Sohini GhoshJill A. OharM. Bradley Drummond. (2017) Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 30:6, pages 381-387.
Crossref
Crossref
Ayah Shakshuki & Remigius U. Agu. (2017) Improving the Efficiency of Respiratory Drug Delivery: A Review of Current Treatment Trends and Future Strategies for Asthma and Chronic Obstructive Pulmonary Disease. Pulmonary Therapy 3:2, pages 267-281.
Crossref
Crossref
Joachim H. Ficker, Klaus F. Rabe & Tobias Welte. (2017) Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Pulmonary Pharmacology & Therapeutics 45, pages 19-33.
Crossref
Crossref
Mario Cazzola, Josuel Ora, Ermanno Puxeddu & Paola Rogliani. (2017) Indacaterol/Glycopyrronium Combination for COPD. Pulmonary Therapy 3:1, pages 45-57.
Crossref
Crossref
Alfred Haynes, David Geller, Jeffry Weers, Brian Ament, Richard Pavkov, Richard Malcolmson, Laurie Debonnett, Paul Mastoridis, Anthony Yadao & Silvia Heuerding. (2016) Inhalation of tobramycin using simulated cystic fibrosis patient profiles. Pediatric Pulmonology 51:11, pages 1159-1167.
Crossref
Crossref
Shelby Dougall, Jennifer Bolt, William Semchuk & Tanya Winkel. (2016) Inhaler assessment in COPD patients. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 149:5, pages 268-273.
Crossref
Crossref
Peter Haidl, Stefan Heindl, Karsten Siemon, Maria Bernacka & Rolf Michael Cloes. (2016) Inhalation device requirements for patients' inhalation maneuvers. Respiratory Medicine 118, pages 65-75.
Crossref
Crossref
Federico Lavorini, Claudia Mannini, Elisa Chellini & Giovanni A. Fontana. (2016) Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices. Drugs & Aging 33:7, pages 461-473.
Crossref
Crossref
Rosalind H.E. Chong, Brian E. Jones, Fernando Díez, James C. Birchall & Sion A. Coulman. (2016) Evaluating the sensitivity, reproducibility and flexibility of a method to test hard shell capsules intended for use in dry powder inhalers. International Journal of Pharmaceutics 500:1-2, pages 316-325.
Crossref
Crossref
David Price & Henry Chrystyn. (2015) Concept review of dry powder inhalers: correct interpretation of published data. Multidisciplinary Respiratory Medicine 10:1.
Crossref
Crossref
Vincent Ninane, Jan Vandevoorde, Didier Cataldo, Eric Derom, Giuseppe Liistro, Evert Munghen, Rudi Peché, Marc Schlesser, Geert Verleden & Walter Vincken. (2015) New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences. Respiratory Medicine 109:11, pages 1430-1438.
Crossref
Crossref
Simone R. Carvalho, Alan B. Watts, Jay I. Peters & Robert O. WilliamsIIIIII. 2015. Pulmonary Drug Delivery. Pulmonary Drug Delivery
35
62
.
Jeffry G. WeersAndrew R. ClarkNagaraja RaoKeith UngAlfred HaynesSanjeev K. KhindriSheryl A. PerrySurendra MachineniPaul Colthorpe. (2015)
In Vitro–In Vivo
Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler
®
. Journal of Aerosol Medicine and Pulmonary Drug Delivery 28:4, pages 268-280.
Crossref
Crossref
Kai Berkenfeld, Alf Lamprecht & Jason T. McConville. (2015) Devices for Dry Powder Drug Delivery to the Lung. AAPS PharmSciTech 16:3, pages 479-490.
Crossref
Crossref
Ji Jiang, Lilly Li, Hequn Yin, Ralph Woessner, Corinne Emotte, Ruobing Li, Sanjeev Khindri & Hu Pei. (2014) Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers. European Journal of Drug Metabolism and Pharmacokinetics 40:2, pages 203-208.
Crossref
Crossref
Nicola Scichilone, Alida Benfante, Marialuisa Bocchino, Fulvio Braido, Pierluigi Paggiaro, Alberto Papi, Pierachille Santus & Alessandro Sanduzzi. (2015) Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?. Pulmonary Pharmacology & Therapeutics 31, pages 63-67.
Crossref
Crossref
Girolamo Pelaia, Rosario Maselli & Luca Gallelli. (2014) Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium. Multidisciplinary Respiratory Medicine 9:1.
Crossref
Crossref
Alessandro Sanduzzi, Piero Balbo, Piero Candoli, Giousuè A Catapano, Paola Contini, Alessio Mattei, Giovanni Puglisi, Luigi Santoiemma & Anna A Stanziola. (2014) COPD: adherence to therapy. Multidisciplinary Respiratory Medicine 9:1.
Crossref
Crossref
Stefano Nardini, Gianna Camiciottoli, Salvatore Locicero, Rosario Maselli, Franco Pasqua, Giovanni Passalacqua, Riccardo Pela, Alberto Pesci, Alfredo Sebastiani & Alessandro Vatrella. (2014) COPD: maximization of bronchodilation. Multidisciplinary Respiratory Medicine 9:1.
Crossref
Crossref
Claudio M Sanguinetti. (2014) The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients. Multidisciplinary Respiratory Medicine 9:1.
Crossref
Crossref
Lorraine Murphy, Stephen Rennard, James Donohue, Mathieu Molimard, Ronald Dahl, Kai-Michael Beeh, Juergen Dederichs, Hans-Jürgen Fülle, Mark Higgins & David Young. (2014) Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD. Drugs 74:14, pages 1635-1657.
Crossref
Crossref
Girolamo Pelaia, Rosario Maselli & Maria Gabriella Matera. (2014) Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium. Pharmacology 94:5-6, pages 249-258.
Crossref
Crossref
David Young, Lee Wood, Dilraj Singh & Juergen Dederichs. 2014. Indacaterol. Indacaterol
117
128
.
Barbara M. Torrisi, James C. Birchall, Brian E. Jones, Fernando Díez & Sion A. Coulman. (2013) The development of a sensitive methodology to characterise hard shell capsule puncture by dry powder inhaler pins. International Journal of Pharmaceutics 456:2, pages 545-552.
Crossref
Crossref
C. Compton, D. McBryan, E. Bucchioni & F. Patalano. (2013) The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 26:5, pages 562-573.
Crossref
Crossref
Donald A. MahlerLaurie A. WatermanAlex H. Gifford. (2013)
Prevalence and COPD Phenotype for a Suboptimal Peak Inspiratory Flow Rate against the Simulated Resistance of the Diskus
®
Dry Powder Inhaler
. Journal of Aerosol Medicine and Pulmonary Drug Delivery 26:3, pages 174-179.
Crossref
Crossref
Edward M. Kerwin & James Williams. (2013) Indacaterol 75 µg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective. Therapeutic Advances in Respiratory Disease 7:1, pages 25-37.
Crossref
Crossref
Donald P Tashkin & Gary T Ferguson. (2013) Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respiratory Research 14:1, pages 49.
Crossref
Crossref
Kate McKeage. (2012) Indacaterol. Drugs 72:4, pages 543-563.
Crossref
Crossref
Dennis J. Cada, Terri L. Levien & Danial E. Baker. (2012) Indacaterol. Hospital Pharmacy 47:3, pages 219-236.
Crossref
Crossref
Marta Drummond. (2012) A propósito do papel do Indacaterol na patologia obstrutiva das vias aéreas: PRÓ. Revista Portuguesa de Pneumologia 18:1, pages 5-7.
Crossref
Crossref
M. Drummond. (2012) About the role of indacaterol in obstructive airways disorder: PRO. Revista Portuguesa de Pneumologia (English Edition) 18:1, pages 5-7.
Crossref
Crossref
DJ Myers, DA Spyker, K Dinh, RJ Quintana, SA Biondi & JV Cassella. (2011)
Consistency of dosing with a thermal aerosol generation system:
in vitro
and
in vivo
correlation
. Future Medicinal Chemistry 3:13, pages 1719-1733.
Crossref
Crossref
Claus Vogelmeier & Donald Banerji. (2011) NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 5:3, pages 163-173.
Crossref
Crossref
Federico L Dente, Elena Bacci, Barbara Vagaggini & Pierluigi Paggiaro. (2011) Role of indacaterol in the management of asthma and chronic obstructive pulmonary disease. Clinical Investigation 1:4, pages 589-602.
Crossref
Crossref